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 Heterozygous mice (aMHC403/þ) expressing the human
hypertrophic cardiomyopathy (HCM) disease causing
mutation Arg403Gln exhibit cardinal features of HCM.
 This study investigated the role of L-type Ca2D channel
(ICa-L) in regulating mitochondrial function in
Arg403Gln (aMHC403/þ) mice.
 Activation of ICa-L in aMHC403/þmice caused a signiﬁcantly
greater increase in mitochondrial membrane potential and
metabolic activity when compared to wild-type mice.
 Increases in mitochondrial membrane potential and
metabolic activity were attenuated with ICa-L antagonists
and when F-actin or b-tubulin were depolymerized.
 ICa-L antagonists may be effective in reducing the
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ABBR EV I A T I ON S
AND ACRONYMS
[Ca2þ]i = intracellular calc
HCM = hypertrophic
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ICa-L = L-type Ca2D channe
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VDAC = voltage-dependen
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Jm = mitochondrial memb
potential
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62SUMMARYium
l
t
ranHeterozygous mice (aMHC403/þ) expressing the human disease-causing mutation Arg403Gln exhibit cardinal features
of hypertrophic cardiomyopathy (HCM) including hypertrophy, myocyte disarray, and increased myocardial ﬁbrosis.
Treatment of aMHC403/þmice with the L-type calcium channel (ICa-L) antagonist diltiazem has been shown to decrease
left ventricular anterior wall thickness, cardiac myocyte hypertrophy, disarray, and ﬁbrosis. However, the role of the ICa-L
in the development of HCM is not known. In addition to maintaining cardiac excitation and contraction in myocytes,
the ICa-L also regulates mitochondrial function through transmission of movement of ICa-L via cytoskeletal proteins
to mitochondrial voltage-dependent anion channel. Here, the authors investigated the role of ICa-L in regulating
mitochondrial function in aMHC403/þmice. Whole-cell patch clamp studies showed that ICa-L current inactivation kinetics
were signiﬁcantly increased in aMHC403/þcardiac myocytes, but that current density and channel expression were
similar to wild-type cardiac myocytes. Activation of ICa-L caused a signiﬁcantly greater increase in mitochondrial
membrane potential and metabolic activity in aMHC403/þ. These increases were attenuated with ICa-L antagonists and
following F-actin or b-tubulin depolymerization. The authors observed increased levels of ﬁbroblast growth factor-21
in aMHC403/þmice, and altered mitochondrial DNA copy number consistent with altered mitochondrial activity and
the development of cardiomyopathy. These studies suggest that the Arg403Gln mutation leads to altered functional
communication between ICa-L and mitochondria that is associated with increased metabolic activity, which may
contribute to the development of cardiomyopathy. ICa-L antagonists may be effective in reducing the cardiomyopathy
in HCM by altering metabolic activity. (J Am Coll Cardiol Basic Trans Sci 2016;1:61–72) ©2016 The Authors. Published by
Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).M yosin heavy chain (MHC) consists of amyosin carboxyl terminal rod and anamino terminal globular head that
interacts with actin (1,2). During contraction, force is
transduced via a hinge region between these 2
domains, allowing attachment–detachment of the
myosin head with actin ﬁlaments. There are 2
cardiac-speciﬁc isoforms of MHC: a-cardiac MHC and
b-cardiac MHC. In humans, b-MHC predominates in
adult life, accounting for >90% of ventricular myosin
(3). Genetic mutations in contractile protein b-MHC
account for approximately 40% of genotyped
families with hypertrophic cardiomyopathy (HCM)
(4–6).
The human b-MHC mutation MYH7 Arg403Gln
causes a severe form of HCM characterized by early-
onset and progressive myocardial dysfunction withea high incidence of sudden cardiac death
(7). However, the relationship between the
gene mutation and phenotype is poorly
understood.
Heterozygous mice expressing the human
disease–causing mutation Arg403Gln
(aMHC403/þ) exhibit hallmark features of the
cardiomyopathy, including hypertrophy,
myocyte disarray, and increased myocardial
ﬁbrosis (8). We have previously demonstrated
that treatment of aMHC403/þ mice with the
L-type calcium channel (ICa-L) antagonistdiltiazem decreases left ventricular anterior wall
thickness, cardiac myocyte hypertrophy, disarray, and
ﬁbrosis (9,10). In addition, administration of diltiazem
to patients with HCM improves left ventricular end-
diastolic diameter and left ventricular wall thickness-
to-dimension ratio (10). However, the role of ICa-L in
development of the cardiomyopathy is currently
unknown.
The cytoskeleton consists of microtubules
composed of tubulin, microﬁlaments composed of
actin, and intermediate ﬁlaments, and is recognized
as a modulator of cell morphology, motility, intra-
cytoplasmic transport, and mitosis (11,12). Cytoskel-
etal proteins also regulate the function of proteins
in the plasma membrane (13,14). ICa-L is anchored to
F-actin and b-tubulin that regulate ICa-L activation
and inactivation kinetics (15–18). In addition, the
mitochondrial outer membrane contains docking
sites for cytoskeletal proteins that can regulate
mitochondrial function (12,19,20).
Calcium inﬂux through the ICa-L or dihydropyridine
channel is critical to cardiac excitation and contrac-
tion. ICa-L can also regulate mitochondrial function.
Activation of ICa-L with voltage clamp of the plasma
membrane or with application of the dihydropyridine
receptor agonist Bay K8644 (BayK(-)) is sufﬁcient to
increase cytosolic and mitochondrial calcium, in
addition to NADH production, superoxide generation,
and metabolic activity in a calcium-dependent
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63manner (21,22). Activation of ICa-L can also increase
mitochondrial membrane potential (Jm) in a calcium-
independent manner (21). The response is reversible
upon inactivation of ICa-L and is in part dependent on
F-actin ﬁlaments because depolymerization of F-
actin prevents the response (21). The beta subunit (b2)
of ICa-L is tethered to cytoskeletal proteins. Prevent-
ing movement of the b2 subunit with application of a
peptide derived against the alpha-interacting domain
of ICa-L attenuates the increase in Jm (21). Therefore,
ICa-L inﬂuences metabolic activity through trans-
mission of movement of ICa-L via cytoskeletal
proteins.
We and others have demonstrated that aMHC403/þ
mice exhibit increased actin–myosin sliding velocity,
force generation, increased ATPase activity, and ADP
concentration (23,24). Here, we sought to identify
whether the Arg403Gln mutation leads to mito-
chondrial dysfunction in cardiac myocytes isolated
from 30- to 50-week-old aMHC403/þ mice with
established cardiomyopathy (8,25). Speciﬁcally, we
investigated whether the mutation resulted in
altered communication between the ICa-L and mito-
chondria, and subsequently, altered metabolic
activity.
METHODS
MOUSE MODELS. Male 30- to 50-week-old and 10- to
15-week-old mice expressing the human dis-
ease–causing mutation Arg403Gln (aMHC403/þ) were
generated (8) and studied. The mice develop car-
diomyopathy by 30 to 50 weeks as evidenced
by echocardiography and heart weight to body
weight measurements (Supplemental Table 1).
Genotype-negative littermate age-matched male mice
were used as wild-type (wt) controls. Hearts were
extracted as approved by The Animal Ethics Com-
mittee of The University of Western Australia in
accordance with the Australian Code of Practice for
the Care and Use of Animals for Scientiﬁc Purposes
(NH&MRC, 8th Edition, 2013). Cardiac myocytes were
isolated as previously described (26,27). Detailed
methods are provided in the Supplemental Methods.
DATA ACQUISITION FOR PATCH CLAMP STUDIES.
Whole-cell conﬁguration of the patch clamp tech-
nique was used to measure changes in ICa-L currents
in intact cardiac myocytes as described previously
(28,29). Detailed methods are provided in the
Supplemental Methods.
FLUORESCENT STUDIES. All studies were performed
in intact mouse cardiac myocytes at 37C as previ-
ously described. Intracellular calcium ([Ca2þ]i) was
monitored using Fura-2 (29). Superoxide generationwas assessed using dihydroethidium (29). Fluores-
cent indicator JC-1 was used to measure Jm (29).
Flavoprotein autoﬂuorescence was used to measure
ﬂavoprotein oxidation (30). Detailed methods are
provided in the Supplemental Methods.
MTT ASSAY. The rate of cleavage of the tetrazolium
salt MTT to formazan by the mitochondrial electron
transport chain was measured spectrophotometri-
cally as previously described (21,26). Detailed
methods are provided in the Supplemental Methods.
MITOCHONDRIAL RESPIRATION STUDIES AND DNA
COPY NUMBER. Mitochondrial respiration was
measured in mitochondria isolated from 3 pooled wt
and 3 pooled aMHC403/þ mouse hearts at 37C as
previously described (31). Detailed methods are pro-
vided in the Supplemental Methods. Mitochondrial
DNA copy number was determined by quantitative
reverse-transcription polymerase chain reaction as
previously described (32).
QUANTITATIVE REVERSE-TRANSCRIPTION POLYMERASE
CHAIN REACTION. Transcript abundance of mito-
chondrial transcription factor A (TFAM), peroxisome
proliferator-activated receptor gamma (PPARg) and
peroxisome proliferator-activated receptor gamma
coactivator (PGC)-1 was measured as previously
described (33). Detailed methods are provided in the
Supplemental Methods.
SAMPLE PREPARATION FOR TRANSMISSION ELECTRON
MICROSCOPY AND CONFOCAL IMAGING. For trans-
mission electron microscopy, cardiac tissue samples
were imaged on a JEOL JEM-2100 electron micro-
scope (JEOL, Akishima, Japan). For confocal imaging,
cardiac myocytes tripled stained with MitoTracker
(mitochondria), phalloidin (F-actin) and DAPI (nuclei)
(Thermo Fisher Scientiﬁc, Massachusetts) were
imaged on an Olympus IX71 inverted ﬂuorescent mi-
croscope (Olympus, Tokyo, Japan).
Detailed methods are provided in the
Supplemental Methods.
STATISTICAL ANALYSIS. Results are reported as
mean  SEM or SD where indicated. Statistical com-
parisons of parametric data were made using the
unpaired Student t test (GraphPad Prism version 5.04,
GraphPad Software, La Jolla, California). Statistical
comparisons of non-parametric data were made using
the Mann-Whitney U test, or Kruskal-Wallis test
(GraphPad Prism version 5.04).
RESULTS
aMHC403/þ CARDIAC MYOCYTES EXHIBIT ALTERED
ICa-L INACTIVATION KINETICS. Using the patch
clamp technique, we measured ICa-L currents in
FIGURE 1 Myocytes Isolated From aMHC403/þ Hearts Exhibit Altered Inactivation Kinetics
Continued on the next page
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65aMHC403/þ myocytes (Figure 1A). We found no dif-
ference in ICa-L current density recorded in
aMHC403/þ versus wt myocytes (aMHC403/þ 3.86  0.
26 pA/pF vs. wt 3.91  0.30, p ¼ NS) (Figures 1C and
1F). These data suggest that ICa-L expression is not
altered in aMHC403/þ myocytes. To further conﬁrm
this, we probed immunoblots of ICa-L protein isolated
from aMHC403/þ hearts with an antibody directed
against the pore-forming a1C subunit. Densitometry
analysis indicated a slight increase (8.2  0.6%) in
a1C subunit expression in aMHC403/þ hearts
(Supplemental Figures 1A and 1B), but this did not
appear to be sufﬁcient to increase peak inward cur-
rent and current density (Figures 1A, 1C, and 1F).
However, inactivation of the current was signiﬁ-
cantly faster in aMHC403/þ versus wt myocytes
(aMHC403/þ: s1 ¼ 32.76  1.96 versus wt: s1 ¼ 40.68 
2.49, p < 0.05) (Figure 1B). Similar results were ob-
tained when barium was used as the charge carrier
indicating that changes in calcium were not medi-
ating alterations in current inactivation (Figures 1H
to 1J). The total integral of current in aMHC403/þ
myocytes were signiﬁcantly less compared with wt
myocytes, whereas no difference in activation inte-
gral was observed (Figures 1D and 1E). No difference
in steady-state inactivation was observed in
aMHC403/þ versus wt myocytes (Figure 1G). Consis-
tent with our results indicating no difference in ICa-L
current density or peak inward current in aMHC403/þ
myocytes, we found no difference in intracellular
calcium ([Ca2þ]i) in aMHC403/þ versus wt myocytes
(Supplemental Figures 2A to 2C).
The b2 subunit of ICa-L is bound to the a1C subunit of
ICa-L and plays an important role in ICa-L kinetics (34).
We probed immunoblots of ICa-L protein with an
antibody directed against the b2 subunit. No signiﬁ-
cant alteration in b2 subunit expression was observed
in aMHC403/þ versus wt hearts (Supplemental
Figures 1C and 1D). Because the b2 subunit of ICa-L is
tethered to F-actin ﬁlaments that also tightly regulate
the function of ICa-L (15–17), these data suggest that
cytoskeletal architecture rather than altered a1C sub-(A) Representative ICa-L current traces from aMHC403/þ (130 pF) and wild
rate of inactivation (tau) of current for aMHC403/þ and wt myocytes ﬁtte
current density, and (D) activation integral and (E) total integral of curr
(I–V) relationship and (G) voltage dependency of steady-state inactivatio
(H) Representative ICa-L current traces recorded from aMHC403/þ (100 pF
(I) Mean  SEM of inactivation (tau) of current for aMHC403/þ and wt m
carrier (i, s 1; and ii, s 2). (J)Mean  SEM of current density for all myocyt
for comparisons in B and C; Mann-Whitney test was used for compariso
FIGURE 1 Continuedunit or b2 subunit expression may be responsible for
altered inactivation of ICa-L current in aMHC403/þ
myocytes.
aMHC403/þ CARDIAC MYOCYTES EXHIBIT A SIGNIFICANTLY
LARGER INCREASE IN Jm FOLLOWING ACTIVATION OF
ICa-L. Increased mitochondrial Ca2þ uptake is associ-
ated with an increase in Jm. However, Jm can func-
tion independently of changes in [Ca2þ]i in the range
of 0 to 400 nmol/l (35). We have previously shown
that adult guinea pig cardiac myocytes exhibit
increased Jm following activation of ICa-L under
calcium-free conditions (21). The response is depen-
dent upon an intact cytoskeletal architecture (21).
Here, we ﬁnd that application of BayK(-) elicits a
signiﬁcant increase in Jm in aMHC403/þ and wt
myocytes pre-incubated in calcium-free and EGTA
containing HEPES-Buffered Solution for at least 3
hours (assessed as changes in JC-1 ﬂuorescence)
(Figures 2A to 2C). The responses were similar to
those recorded in 2.5 mmol/l calcium containing
Hepes-Buffered Solution (Supplemental Figure 3A).
However the ratio of the response was signiﬁcantly
larger in aMHC403/þ versus wt myocytes (Figure 2D).
The responses could be prevented with application
of ICa-L antagonists nisoldipine or diltiazem
(Figures 2A to 2C). Application of BayK(þ) did not
signiﬁcantly alter Jm in aMHC403/þ or wt myocytes
(Figures 2A to 2C). Sodium cyanide was added to
collapse Jm demonstrating that the signal was
mitochondrial and indicative of Jm (Figures 2A and
2B). No difference was observed in basal Jm in
aMHC403/þ versus wt myocytes (Supplemental
Figures 3B and 3C). These data demonstrate that
activation of ICa-L causes a signiﬁcantly greater in-
crease in Jm in myocytes isolated from aMHC403/þ
hearts compared with wt myocytes, and the response
does not require calcium.
The b2 subunit of ICa-L is tethered to F-actin via
subsarcolemmal stabilizing protein AHNAK (15).
Mitochondria also associate with F-actin via mito-
chondrial docking proteins (36–38). We have previ--type (wt) (120 pF) myocytes. (Inset) Pulse protocol. (B) Mean  SEM
d with 2 exponential functions (i, s 1; and ii, s 2). Mean  SEM of (C)
ent for aMHC403/þ and wt myocytes. (F) Current/voltage
n measured in aMHC403/þ and wt myocytes. (Insets) Pulse protocols.
) and wt (100 pF) with barium as charge carrier. (Inset) Pulse protocol.
yocytes ﬁtted with 2 exponential functions with barium as charge
es with barium as charge carrier. The unpaired Student t test was used
ns in D to G and I to J.
FIGURE 2 aMHC403/þ Cardiac Myocytes Exhibit a Signiﬁcantly Larger Increase in Jm Following Activation of ICa-L
Representative ratiometric JC-1 ﬂuorescence recorded in (A) wt myocytes and (B) aMHC403/þ myocytes before and after exposure to 10 mmol/l
BayK(þ) or BayK(-)  15 mM nisoldipine (Nisol) or diltiazem (Dilt) under calcium-free conditions (0 mmol/l Ca2þ). Arrow indicates addition
of drugs. NaCN: 40 mmol/l sodium cyanide. (C) Mean  SEM of JC-1 ﬂuorescence for all myocytes exposed to BayK(þ), BayK(-), Nisol, Dilt,
5 mmol/l latrunculin A (Latrunc), or 1 mmol/l colchicine (Colch) as indicated. Latrunc and Colch were added 20 min and 3.5 h before commencing
basal Jm recording, respectively. (D) Ratio of increase in JC-1 ﬂuorescence after addition of BayK(-). The Kruskal-Wallis test was used for
all comparisons. ICa-L ¼ L-type Ca2þ channel.
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66ously demonstrated that ICa-L regulates mitochondrial
function due to an association between ICa-L and the
mitochondria via cytoskeletal protein F-actin (21,26).
We exposed aMHC403/þ myocytes to F-actin depoly-
merizing agent latrunculin A. Under calcium-free
conditions, the increase in Jm in response to
BayK(-) was attenuated in aMHC403/þ and wt myo-
cytes (Figure 2C). These data indicate that elevated
Jm in response to activation of ICa-L is dependent on
cytoskeletal protein F-actin.
Regulation of Jm is in part dependent on the
mitochondrial voltage-dependent anion channel
(VDAC) (39,40). We have previously demonstrated
that directly blocking VDAC (and anion transport
from the outer mitochondrial membrane) mimics the
effect of BayK(-) on Jm in wt mouse myocytes (26,41).
In addition, it is known that the cytoskeletal protein
b-tubulin associates with and regulates the function
of VDAC (42). Therefore, we examined whether
BayK(-)–induced alterations in Jm were dependentupon b-tubulin in aMHC403/þ myocytes by incubating
myocytes in the b-tubulin depolymerizing agent
colchicine. Under calcium-free conditions, the in-
crease in Jm in response to BayK(-) was attenuated in
aMHC403/þ and wt myocytes (Figure 2C). These data
indicate that the increase in Jm in response to acti-
vation of ICa-L is dependent on cytoskeletal protein b-
tubulin.
aMHC403/þ CARDIAC MYOCYTES EXHIBIT A SIGNIFICANTLY
LARGER INCREASE IN METABOLIC ACTIVITY IN RESPONSE
TO ACTIVATION OF ICa-L. Metabolic activity is depen-
dent upon oxygen consumption and electron ﬂow
down the inner mitochondrial membrane. Applica-
tion of BayK(-) elicited a signiﬁcant increase in
metabolic activity in both aMHC403/þ and wt myo-
cytes (Figures 3A and 3B). However, the ratio of the
response was signiﬁcantly larger in aMHC403/þ versus
wt myocytes (Figure 3C). Both responses could be
prevented with application of nisoldipine or the
mitochondrial Ca2þ uniporter inhibitor Ru360, but
FIGURE 3 aMHC403/þ Cardiac Myocytes Exhibit a Signiﬁcantly Larger Increase in Metabolic Activity in Response to Activation of ICa-L
(A) Formation of formazan measured as change in absorbance in wt and aMHC403/þ myocytes after addition of 10 mmol/l BayK(þ) or BayK(-).
(B) Mean  SEM of increases in absorbance for all myocytes exposed to BayK(þ), BayK(-), 10 mmol/l nisoldipine (Nisol), 5 mmol/l Ru360,
5 mmol/l ryanodine (RyR), or 20 mmol/l oligomycin (Oligo) as indicated. (C) Ratio of increase in absorbance after addition of BayK(-).
The Kruskal-Wallis test was used for all comparisons. Abbreviations as in Figures 1 and 2.
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67not ryanodine (Figure 3B). Application of BayK(þ) did
not signiﬁcantly alter metabolic activity in aMHC403/þ
or wt myocytes (Figures 3A and 3B). Application of
ATP synthase blocker oligomycin signiﬁcantly
decreased metabolic activity in aMHC403/þ and wt
myocytes conﬁrming the cells were metabolically
active (Figure 3B).
We examined changes in mitochondrial electron
transport by measuring alterations in ﬂavoprotein
oxidation in myocytes isolated from aMHC403/þ
hearts in response to activation of ICa-L. Application
of BayK(-) caused a signiﬁcant increase in ﬂavopro-
tein oxidation in aMHC403/þ and wt myocytes
(Figures 4A to 4C). The ratio of the increase in
ﬂavoprotein oxidation was signiﬁcantly larger in
aMHC403/þ versus wt myocytes (Figure 4D). Both re-
sponses could be prevented with application of
nisoldipine (Figure 4C). Application of BayK(þ) did
not signiﬁcantly alter ﬂavoprotein oxidation in
aMHC403/þ or wt myocytes (Figures 4A to 4C). FCCP
(carbonyl cyanide 4-(triﬂuoromethoxy) phenyl-
hydrazone) was added at the end of each experiment
to increase ﬂavoprotein signal conﬁrming the signal
was mitochondrial in origin (Figures 4A to 4C). Thesedata indicate that activation of ICa-L causes a signif-
icantly greater increase in metabolic activity in
myocytes isolated from aMHC403/þ compared to wt
hearts.
RESPIRATORY COMPLEX ACTIVITY IS SIMILAR IN
MITOCHONDRIA ISOLATED FROM HEARTS OF
aMHC403/þ AND wt HEARTS. We performed respira-
tory electron transport chain complex activity and
oxygen consumption measurements on mitochondria
isolated from aMHC403/þ and wt hearts. No differences
were observed in mitochondria isolated from
aMHC403/þ versus wt hearts (Figure 5A). These data
suggest that alterations in mitochondrial function
observed in aMHC403/þ myocytes were cell intrinsic,
and not secondary to hypertrophic remodeling of the
ventricle.
MITOCHONDRIAL DNA COPY NUMBER AND GENE
EXPRESSION ARE ALTERED IN aMHC403/þ HEARTS.
We found that mitochondrial DNA copy number was
increased in aMHC403/þ versus wt hearts (Figure 5B).
This correlated with increased expression of nuclear
encoded regulators of the mitochondrial genome
TFAM, PPARg, and PGC-1 (Figure 5C). Because ﬁbro-
blast growth factor 21 (FGF21) is a marker for
FIGURE 4 aMHC403/þ Cardiac Myocytes Exhibit a Signiﬁcantly Larger Increase In Flavoprotein Oxidation in Response to
Activation of ICa-L
Representative traces of ﬂavoprotein ﬂuorescence recorded in (A) wt and (B) aMHC403/þ myocytes before and after exposure to 10 mmol/l
BayK(-) or BayK(þ). Arrow indicates addition of drugs. (C) Mean  SEM of ﬂavoprotein ﬂuorescence for all myocytes exposed to
BayK(þ), BayK(-), 15 mmol/l nisoldipine (Nisol), or 50 mmol/l FCCP as indicated. (D) Ratio of increase in ﬂavoprotein ﬂuorescence after
addition of BayK(-). The Kruskal-Wallis test was used for all comparisons. Abbreviations as in Figures 1 and 2.
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68mitochondrial dysfunction in myocytes (43,44), we
measured FGF21 in circulating blood from the mice.
We measured a signiﬁcant increase in FGF21 levels in
aMHC403/þ versus wt mice, correlating with the
onset of cardiomyopathy (Figure 5D). Transmission
electron microscopy imaging revealed disordered
mitochondrial distribution in aMHC403/þ versus wt
hearts (Figures 5E and 5F). Additionally, confocal im-
aging revealed disordered mitochondrial distribution
and disorganization of F-actin in aMHC403/þ versus wt
myocytes (Figures 5G and 5H).
PRE-CARDIOMYOPATHIC aMHC403/þ CARDIAC MYOCYTES
EXHIBIT ALTERED ICa-L INACTIVATION KINETICS AND
LARGER INCREASES IN Jm AND METABOLIC ACTIVITY
FOLLOWING ACTIVATION OF ICa-L. We assessed alter-
ations in ICa-L inactivation kinetics and mitochondrial
responses in cardiac myocytes from 10- to
15-week-old aMHC403/þ hearts that had not yet
developed cardiomyopathy (Supplemental Table 1)
(8,25). Using the patch clamp technique, wemeasured ICa-L currents in the myocytes
(Supplemental Figure 4A). Similar to 30- to
50-week-old myocytes, we found no difference in
ICa-L current density in 10- to 15-week-old MHC403/þ
versus age-matched wt myocytes (Supplemental
Figure 4C). However, inactivation of the current
was signiﬁcantly faster in aMHC403/þ myocytes
(Supplemental Figure 4B). Additionally, application
of BayK(-) elicited a signiﬁcantly larger increase in
Jm and ﬂavoprotein oxidation in 10- to 15-week-old
MHC403/þ versus age-matched wt myocytes
(Supplemental Figure 5). The responses could be
prevented with ICa-L antagonist nisoldipine. These
data suggest that altered communication between
ICa-L and the mitochondria precedes the development
of aMHC403/þ cardiomyopathy.
DISCUSSION
The L-type Ca2þ channel plays an important role
in cardiac excitation and contraction. It can also
FIGURE 5 Respiration Is Normal, but Gene Expression Is Altered in Mitochondria Isolated From aMHC403/þ Hearts
(A) Respiration and mitochondrial electron transport chain complex activity in mitochondria isolated from 3 pooled wt and 3 pooled aMHC403/þ
hearts. (B) Mean  SD of MtDNA copy number normalized to 18S rDNA. (C) Mean  SD of gene expression of aMHC403/þ MtDNA copy number
regulators TFAM, PPARg and PGC1 relative to wt. (D) Mean  SD of FGF21. (E and F) Representative TEM images demonstrating disordered
distribution of mitochondria in aMHC403/þ (F) versus wt (E) heart sections. M ¼ mitochondria; S ¼ sarcomere. Scale ¼ 1 mm. (G and H) Confocal
imaging demonstrating disordered mitochondrial distribution and disorganization of F-actin in representative aMHC403/þ (H) versus wt (G)
myocytes. Mitochondria shown in red (MitoTracker), F-actin shown in green (phalloidin), nuclei shown in blue (DAPI). Scale ¼ 10 mm. The
Mann-Whitney test was used for all comparisons. MtDNA ¼ mitochondrial DNA; TEM ¼ transmission electron microscopy; wt ¼ wild type.
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69inﬂuence metabolic activity through transmission of
movement of the b subunit via cytoskeletal proteins
(21,26). We investigated whether the Arg403Gln mu-
tation in contractile protein b-MHC results inimpaired communication between ICa-L and the
mitochondria, and subsequently, altered metabolic
function. We ﬁnd that ICa-L current inactivates more
rapidly in myocytes from aMHC403/þ hearts (Figure 1).
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70This appears to occur as a result of tethering of ICa-L
to cytoskeletal proteins, and is consistent with
ﬁndings that dissociation of microtubules or depo-
lymerization of actin alters ICa-L inactivation rate
(16,17,45,46). Peak inward current, current density,
and ICa-L expression were not signiﬁcantly altered
in aMHC403/þ myocytes. Consistent with this, basal
and BayK(-)–stimulated increases in [Ca2þ]i and
superoxide production were also no different from
wt myocytes (Supplemental Figure 2). Previous
studies have demonstrated that the relaxation rate
of aMHC403/þ cardiac myocytes is slowed and cal-
cium transients are smaller due to reduced expres-
sion of ryanodine receptors and calsequestrin,
leading to diminished sarcoplasmic reticulum stores
(9,47). Taken together, the ﬁndings demonstrate
that the Arg403Gln mutation is associated with
altered sarcoplasmic reticulum calcium cycling but
does not appear to be associated with signiﬁcant
changes in diastolic Ca2þ or superoxide production
in aged aMHC403/þ hearts.
One factor that inﬂuences metabolic activity and
mitochondrial ATP production is electron ﬂow down
the inner mitochondrial membrane. We demon-
strate that aMHC403/þ cardiac myocytes exhibit a
signiﬁcantly larger increase in Jm, oxygen con-
sumption and ﬂavoprotein oxidation in response to
activation of ICa-L that can be attenuated by ICa-L
antagonist nisoldipine (Figures 2 to 4). The increase
in Jm can also be attenuated by diltiazem. These
data indicate that metabolic activity in aMHC403/þ
myocytes is higher versus wt myocytes. We
demonstrate that this is dependent upon the intact
cellular environment because respiration was
normal in mitochondria isolated from aMHC403/þ
hearts (Figure 5A). In support of this, desmin-null
mice exhibit normal rates of maximal respiration
in isolated mitochondria, but in vivo mitochondrial
respiration is abnormal (20). Because alterations in
mitochondrial function are observed only in the
intact myocyte, we conclude that alterations to the
cell’s intrinsic environment (as evidenced in
Figures 5G and 5H) result in altered communication
between ICa-L and mitochondria, contributing to a
hypermetabolic state in the aMHC403/þ cardiac
myocyte.
We have demonstrated previously that ICa-L
co-immunoprecipitates with many cytoskeletal pro-
teins (21,26). We investigated how the mutation
in the MHC gene leads to alterations in protein-
protein interactions through the cytoskeletal
network. The b2 subunit of the L-type Ca2þ channel
is tightly bound to the a1C subunit via the alpha-interacting domain (48,49). The b2 subunit of the
channel is also tethered to F-actin via sub-
sarcolemmal stabilizing protein AHNAK (15). Mito-
chondria also associate with actin via mitochondrial
docking proteins (36–38), and with b-tubulin via
VDAC (42). Here, we demonstrate that elevated Jm
in response to activation of ICa-L is dependent
on cytoskeletal proteins F-actin and b-tubulin in
the aMHC403/þ cardiac myocyte because expo-
sure of myocytes to either F-actin depolymerizing
agent latrunculin A or b-tubulin depolymerizing
agent colchicine attenuates elevated Jm in re-
sponse to activation of ICa-L (Figure 2C). These
data indicate that the Arg403Gln mutation is asso-
ciated with altered functional communication
between ICa-L and mitochondria via the cyto-
skeletal network, and increased cardiac metabolic
activity.
To determine whether alterations in mitochon-
drial responses occurred before the onset of cardio-
myopathy, we examined ICa-L kinetics and the effect
of activation of ICa-L on Jm and ﬂavoprotein oxida-
tion in myocytes isolated from pre-cardiomyopathic
10- to 15-week-old aMHC403/þ hearts. Similar re-
sponses were recorded to those observed in myo-
cytes from 30- to 50-week-old aMHC403/þ hearts that
had developed cardiomyopathy (Supplemental
Figures 4 and 5). Because the responses were
observed before the development of the cardiomy-
opathy, we conclude that altered communication
between the ICa-L and mitochondria may contribute
to the histology and pathophysiology, speciﬁcally
altered energy reserve and hypercontractility, which
has been identiﬁed in patients with HCM (50). The
ICa-L antagonist diltiazem is effective in preventing
the development of cardiomyopathy in aMHC403/þ
mice and in some patients with identiﬁed MYH7
gene mutations. Our ﬁndings indicate that targeting
ICa-L may be effective in the treatment of cardio-
myopathy by modulating the activity of the ICa-L and
decreasing/restoring metabolic activity. We specu-
late that early intervention involving treatment with
ICa-L antagonist diltiazem may prove beneﬁcial in
regulating metabolic activity and subsequently,
preventing the development of cardiomyopathy
in “at-risk” patients with identiﬁed MYH7 gene
mutations.
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PERSPECTIVES
COMPETENCY INMEDICALKNOWLEDGE:Mutations
in contractile protein b-myosin heavy chain account for
approximately 40% of genotyped families with HCM.
Altered energy reserve has been identiﬁed in patients with
HCM,however the relationship between thegenemutation
and phenotype is poorly understood. L-type Ca2þ channel
antagonists are used clinically to treat patients but the role
of the L-type Ca2þ channel in the development of the
cardiomyopathy is unknown. Here we ﬁnd that the b-
myosin heavy chain mutation Arg403Gln leads to altered
functional communication between the L-type Ca2þ
channel andmitochondria that is associated with increased
cardiac metabolic activity. This may contribute to the
development of the cardiomyopathy because the response
is present prior to the development of cardiomyopathy.
TRANSLATIONAL OUTLOOK: Further studies are
needed to determine cardiac metabolic activity in “at risk”
patients with identiﬁed MYH7 gene mutations before the
development of HCM. On the basis of our ﬁndings, we
speculate that utilizing L-type Ca2þ channel antagonists
as a means of modulating cardiac metabolic activity may
prove beneﬁcial in early intervention and subsequent
prevention of HCM in at-risk patients with identiﬁed
MYH7 gene mutations.
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